All In Biotech

Drug Trial Radar · NCT07217678

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

Last checked: Nov 20, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Feb 9, 2026

Primary completion

Jan 31, 2028

Study completion Jan 31, 2028

Sponsor

Lead sponsor
University of MiamiAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AbbVie
First posted
Oct 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.

Conditions

  • Glaucoma
  • Open-Angle Glaucoma
  • Ocular Hypertension
  • Glaucoma Suspect

Interventions

  • Durysta, Bimatoprost Intracameral Implant 10 µgDrug

    Participants in this arm will receive a one-time injection of Durysta (intracameral bimatoprost 10mcg). Participants will be followed by a total of 3 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Caspase-1 mRNA Expression Following Durysta InjectionTime frame: Baseline, post-injection 1 month, post-injection 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bascom Palmer Eye Institute

    Miami, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.